Antibody partnering terms and agreements market

  • 105 views
Uploaded on

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading …

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
105
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Antibody Partnering Terms and AgreementsMarketThe Antibody Partnering Terms and Agreements report provides comprehensive understandingand unprecedented access to the antibody partnering deals and agreements entered into bythe worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enterantibody partnering deals. The majority of deals are discovery or development stage wherebythe licensee obtains a right or an option right to license the licensors antibody technology.These deals tend to be multicomponent, starting with collaborative R&D, andcommercialization of outcomes.This report provides details of the latest antibody agreements announced in the healthcaresectors, covering:  Antibodies  Antibody-drug conjugates  Monoclonal antibodies Murine mAb Chimeric mAb Humanized mAb Human aAb  Polyclonal AntibodiesUnderstanding the flexibility of a prospective partners negotiated deals terms provides criticalinsight into the negotiation process in terms of what you can expect to achieve during thenegotiation of terms. Whilst many smaller companies will be seeking details of the paymentsclauses, the devil is in the detail in terms of how payments are triggered - contract documentsprovide this insight where press releases do not.Get your copy @ http://www.reportsnreports.com/reports/152018-antibody-partnering-terms-and-agreements.htmlReport Details:Published: November 2012No. of Pages: 376Price: Single User License: US$2695 Corporate User License: US$13475
  • 2. The report also includes numerous tables and figures that illustrate the trends and activities inantibody partnering and dealmaking since 2007.In conclusion, this report provides everything a prospective dealmaker needs to know aboutpartnering in the research, development and commercialization of antibody technologies andproducts.Key benefits  Antibody Partnering Terms and Agreements provides the reader with the following key benefits:  In-depth understanding of antibody deal trends since 2007  Access to headline, upfront, milestone and royalty data  Analysis of the structure of antibody agreements with numerous real life case studies  Comprehensive access to over 1,500 actual antibody contracts entered into by the worlds biopharma companies  Detailed access to actual antibody contracts enter into by the leading fifty bigpharma companies  Insight into the terms included in a antibody agreement, together with real world clause examples  Understand the key deal terms companies have agreed in previous deals  Undertake due diligence to assess suitability of your proposed deal terms for partner companiesReport scopeAntibody Partnering Terms and Agreements is intended to provide the reader with an in-depthunderstanding and access to antibody trends and structure of deals entered into by leadingcompanies worldwide.Antibody Partnering Terms and Agreements includes:  Trends in antibody dealmaking in the biopharma industry since 2007  Analysis of antibody deal structure  Access to headline, upfront, milestone and royalty data  Case studies of real-life antibody deals  Access to over 1,500 antibody contract documents
  • 3.  The leading antibody deals by value since 2007  Most active antibody dealmakers since 2007  The leading antibody partnering resourcesIn Antibody Partnering Terms and Agreements, the available contracts are listed by:  Company A-Z  Headline value  Stage of development at signing  Deal component type  Specific therapy targetEach deal title links via Weblink to an online version of the deal record and where available, thecontract document, providing easy access to each contract document on demand.The Antibody Partnering Terms and Agreements report provides comprehensive access toavailable deals and contract documents for over 1,500 antibody deals.Analyzing actual contract agreements allows assessment of the following:  What are the precise antibody rights granted or optioned?  What is actually granted by the agreement to the partner company?  What exclusivity is granted?  What is the payment structure for the deal?  How are sales and payments audited?  What is the deal term?  How are the key terms of the agreement defined?  How are IPRs handled and owned?  Who is responsible for commercialization?  Who is responsible for development, supply, and manufacture?  How is confidentiality and publication managed?  How are disputes to be resolved?  Under what conditions can the deal be terminated?  What happens when there is a change of ownership?  What sublicensing and subcontracting provisions have been agreed?  Which boilerplate clauses does the company insist upon?  Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?  Which jurisdiction does the company insist upon for agreement law?
  • 4. BenefitsAntibody Partnering Terms and Agreements provides the reader with the following keybenefits:  In-depth understanding of antibody deal trends since 2007  Access to headline, upfront, milestone and royalty data  Analysis of the structure of antibody agreements with numerous real life case studies  Comprehensive access to over 1500 actual antibody deals entered into by the world’s biopharma companies  Detailed access to actual antibody contracts enter into by the leading fifty bigpharma companies  Insight into the terms included in a antibody agreement, together with real world clause examples  Understand the key deal terms companies have agreed in previous deals  Undertake due diligence to assess suitability of your proposed deal terms for partner companiesExplore more reports on Biotechnology @ http://www.reportsnreports.com/market-research/biotechnology/Contact:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.+ 1 888 391 5441sales@reportsandreports.comConnect With Us: